# US 2022/0033486 A1 · Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033486 A1
- Document ID: US20220033486A1
- Status: Published application
- Kind: A1
- Application number: 17/276,882
- Filed: 2019-09-24
- Published: 2022-02-03
- Earliest claimed: 2018-09-25
- Assignees: Inserm (Institut National De La Santé Et De La Recherch MéDicale); Universite De Lille; Centre National de la Recherche Scientifique (CNRS); Institut Pasteur de Lille; Centre Hospitalier Regional Universitarie De Lille
- Applicants: Inserm (Institut National De La Santè Et De La Recherch MéDicale); Université De Lille; Centre National De La Recherche Scientifique (Cnrs); Institut Pasteur De Lille; Centre Hospitalier Regional Universitarie De Lille
- Inventors: Anne TSICOPOULOS; Saliha AIT YAHIA SENDED; Julie NANOU; Mélodie BOUTE; Han VORNG; Cécile CHENIVESSE
- Web page: https://patentgrep.com/patent/US20220033486A1

## CPC

- C07K 16/244: {Interleukins [IL]}
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61P 11/06: Antiasthmatics
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- G01N 33/505: {involving T-cells}
- G01N 33/5088: {of vertebrates}
- G01N 33/56972: {White blood cells}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N 2333/54: Interleukins [IL]
- G01N 2800/122: Chronic or obstructive airway disorders, e.g. asthma COPD
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Bronchial remodelling is a prominent feature of severe asthma and a potential therapeutic target. Some data indicate that Th17 cytokines in particular IL-22 may be involved in remodelling processes in vitro, and in skin remodelling in vivo. The aim of the inventors was to evaluate if Th17 cytokines are involved in bronchial remodelling in a severe model of allergic asthma, and if this was amplified by co-sensitization with NOD2 agonist, MDP, a ligand favouring Th17 polarization. Dog allergen challenge led to a predominant neutrophilic infiltration in Broncho-alveolar lavage (BAL), increased dog-specific IgE production, airways hyperresponsiveness, and increased Th17 cytokine production. Increased bronchial remodeling was observed in dog allergen challenged mice compared to control. IL-22 deficiency decreased airway hyperresponsiveness, bronchial mucus production as well as peribronchial collagen deposition, in the allergen-challenged group. Th17 cytokines in particular IL-22 participate in the bronchial remodeling in a chronic model of neutrophilic asthma, and may represent a therapeutic target in severe asthma.

## Claims

### Claim 1

A method of treating bronchial remodeling in a patient suffering from allergic asthma comprising administering to the patient a therapeutically effective amount of an antagonist of Th17 cytokines.

### Claim 2 (depends on 1)

The method of claim 1 wherein the patient suffers from severe asthma.

### Claim 3 (depends on 1)

The method of claim 1 wherein the antagonist is an antagonist of IL-17.

### Claim 4 (depends on 1)

The method of claim 1 wherein the antagonist is an antagonist of IL-22.

### Claim 5 (depends on 1)

The method of claim 1 wherein the antagonist is selected from the group consisting of IL-17 or IL-22 binding molecules and IL-17 or IL-22 receptor binding molecules.

### Claim 6 (depends on 1)

The method of claim 1 wherein the antagonist is an IL-17 or IL-22 antagonistic antibody.

### Claim 7 (depends on 6)

The method of claim 6 wherein the IL-17 antagonistic antibody binds IL-17A, IL-17 receptor A or IL-17 receptor C.

### Claim 8 (depends on 7)

The method of claim 7 wherein the IL-17 antagonistic antibodies is selected from the group consisting of ixekizumab, secukinumab, and brodalumab.

### Claim 9 (depends on 6)

The method of claim 6 wherein the IL-22 antagonistic antibody binds IL-22, IL22RA1 receptor or IL22RA2 receptor.

### Claim 10 (depends on 9)

The method of claim 9 wherein the antagonistic antibody is fezakinumab.

### Claim 11 (depends on 1)

The method of claim 1 wherein the antagonist is a polypeptide comprising a functional equivalent of a receptor subunit of the cytokine.

### Claim 12 (depends on 1)

The method of claim 1 wherein the antagonist is an inhibitor of the expression of Th17 cytokine or one of its receptors.
